Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-61

Okay, wow thank you!

I think there is clearly more to the story with CF33 / Vaxinia - Then a potent tool that can be used to treat all solid tumours.

Time will tell on the MAST study, but this adds to my concern CF 33 is struggling to get the job done on TNBC.

The other concern I have with the MAST study is the IT mono therapy cohort appears to be powering ahead. But the combination cohorts appear to no longer be progressing or albeit slowed right down. (The 4 cohorts were originally progressing lock at step with each dose escalation).

IT mono is now cleared for 1 X 10 to the 9
IT combination is still dosing in 3 X 10 to the 7

I think the gap is reaching a point where the company sould tell us what they are seeing in combination and why recruitment has slowed.